Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance

Core Insights - Bavarian Nordic A/S completed the sale of its Priority Review Voucher (PRV) for a cash consideration of USD 160 million [1] - The net proceeds from the sale, after deducting royalties and transaction costs, amount to DKK 810 million, which will be recognized as other operating income [2] - The company's revenue expectations for 2025 remain unchanged, with a guided EBITDA margin of 26-30% for regular business, while the total EBITDA margin is expected to be in the range of 40-42% when including the extraordinary income from the PRV sale [2][3] Financial Guidance for 2025 - Revenue guidance is set between DKK 5,700 million and DKK 6,700 million [3] - Public Preparedness revenue is expected to be between DKK 3,000 million and DKK 4,000 million [3] - Travel Health revenue is projected at DKK 2,500 million [3] - Other income is estimated at DKK 200 million [3] - The EBITDA margin for regular business is guided at 26% to 30% [3] - Other net operating income from the PRV sale is DKK 810 million [3] - The total EBITDA margin, including extraordinary income, is expected to be between 40% and 42% [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines [4] - The company is a preferred supplier of mpox and smallpox vaccines to governments, enhancing public health preparedness [4] - Bavarian Nordic also has a leading portfolio of travel vaccines [4]